More News

Clarifi Imaging System for Microvascular Assessment Receives CE Mark An Important Milestone for Modulim

The CE Mark certification allows Modulim to now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

The Ultimate End of Life Planning Checklist

With Pillar, you can get ahead of that by proactively planning. Take things one day at a time so you can be less stressed in the future and focus more on the real things that matter – the person you love.

Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round

Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT,announced the closing of a Series B equity financing of $26 million. Investors in the round included a mix of existing investors from previous rounds, such as Shavit Capital, Medison Ventures, and OurCrowd, who continue to demonstrate support for the clinical development of Alpha DaRT, as well as a number of new private and family office investors primarily from Israel and North America.

During the last year, Alpha Tau Medical successfully completed its first-in-human clinical trial of Alpha DaRT with squamous cell carcinoma patients from Italy and Israel. The impressive results from this study, published in the prestigious International Journal of Radiation Oncology, Biology, Physics (known as the “Red Journal”) were subsequently applauded in this recent editorial in the same journal.

Alpha Tau Medical is now conducting clinical trials in multiple clinical indications across the world, including its first US trial at Memorial Sloan Kettering Cancer Center in New York, a pancreatic cancer trial at CHUM in Montreal, and trials at three academic institutions in Japan. The Company is also establishing new global manufacturing facilities in Israel and elsewhere and is in the middle of a process for CE marking for its first indication. These activities and others will be supported by the proceeds of this financing.

CEO Uzi Sofer commented, “We are humbled by the groundswell of continued support we’ve seen from both existing and new investors. This will enable us to push forward our mission to help cancer patients across the world, even during these challenging times in which COVID-19 is the focus of everyone’s health concerns.”

CFO Raphi Levy added, “We have been very fortunate to continue our progress at full speed across all fronts, including R&D, clinical and operations, and now financing as well, even during a period of global turmoil. As concerns associated with systemic cancer therapies that affect the immune system have become more salient, we see strong interest in our trials from clinicians, patients, and investors who recognize the advantages of a focused and highly potent cancer therapy.”

Alpha DaRT™ (Diffusing Alpha-emitters Radiation Therapy) enables highly potent and conformal alpha-irradiation of solid tumors. The treatment is delivered by intratumoral insertion of radium-224 impregnated seeds. When the radium decays, its short-lived daughters are released from the seed, and disperse while emitting high-energy alpha particles that destroy the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT mainly affects the tumor, sparing the healthy tissue around it. 

Latest Posts

TRIMEDX Acquires Centurion Service Group a Full-Service Surplus Medical Equipment Management Company

TRIMEDX’s acquisition of Centurion Service Group will enhance TRIMEDX’s clinical asset management and informatics solutions.

Clarifi Imaging System for Microvascular Assessment Receives CE Mark An Important Milestone for Modulim

The CE Mark certification allows Modulim to now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

Muvr Labs Is Acquired by Exactech

Orthopaedic surgeon Alexander Sah, MD, in Fremont, Calif. has seen the positive impact of Muvr technology on his practice. “Patients are attracted to the technology because they know our team is monitoring their progress; remarkably, this has caused my patients to take more ownership of their recovery,” he said.

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.